Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Baker

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2021
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohortsKarine Provost, Leonardo Iaccarino, David N Soleimani-Meigooni, et al.
Journal of Clinical and Experimental Neuropsychology|January 6, 2026
Independent, but not synergistic, associations of <i>APOE</i>ε4 and systemic inflammation on cognitive decline: findings from the Women's Health InitiativeHannah M Klinger, Gillian T Coughlan, Kathleen M Hayden, et al.
BMJ Mental Health|July 20, 2025
Agreeing a set of biopsychosocial variables for collection across the UK Eating Disorders Clinical Research Network: a consensus study using adapted nominal group techniqueTom Jewell, Iona Smith, James Downs, et al.
Science Advances|March 5, 2025
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's diseaseGillian T Coughlan, Zoe Rubinstein, Hannah Klinger, et al.
Lancet (London, England)|May 28, 2026
Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant studyGuilherme Povala, Bruna Bellaver, Firoza Z Lussier, et al.
Brain : a Journal of Neurology|November 3, 2020
18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseasesDavid N Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, et al.
Alzheimer'S Research & Therapy|February 2, 2019
<sup>18</sup>F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromesRichard M Tsai, Alexandre Bejanin, Orit Lesman-Segev, et al.
Nature Medicine|November 10, 2022
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Acta Neuropathologica|October 18, 2023
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterationsHolly J Roberts, Sunjong Ji, Alberto Picca, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2021
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohortsKarine Provost, Leonardo Iaccarino, David N Soleimani-Meigooni, et al.
Journal of Clinical and Experimental Neuropsychology|January 6, 2026
Independent, but not synergistic, associations of <i>APOE</i>ε4 and systemic inflammation on cognitive decline: findings from the Women's Health InitiativeHannah M Klinger, Gillian T Coughlan, Kathleen M Hayden, et al.
BMJ Mental Health|July 20, 2025
Agreeing a set of biopsychosocial variables for collection across the UK Eating Disorders Clinical Research Network: a consensus study using adapted nominal group techniqueTom Jewell, Iona Smith, James Downs, et al.
Science Advances|March 5, 2025
Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's diseaseGillian T Coughlan, Zoe Rubinstein, Hannah Klinger, et al.
Lancet (London, England)|May 28, 2026
Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant studyGuilherme Povala, Bruna Bellaver, Firoza Z Lussier, et al.
Brain : a Journal of Neurology|November 3, 2020
18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseasesDavid N Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, et al.
Alzheimer'S Research & Therapy|February 2, 2019
<sup>18</sup>F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromesRichard M Tsai, Alexandre Bejanin, Orit Lesman-Segev, et al.
Nature Medicine|November 10, 2022
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive declineRik Ossenkoppele, Alexa Pichet Binette, Colin Groot, et al.
Acta Neuropathologica|October 18, 2023
Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterationsHolly J Roberts, Sunjong Ji, Alberto Picca, et al.
JAMA Neurology|June 28, 2021
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance ImagingRik Ossenkoppele, Ruben Smith, Niklas Mattsson-Carlgren, et al.
Pageof 5